B+
Bull case
25%
Probability
Target price
$5.16
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
IRWD
IronwoodBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.46
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-25
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+70.4
Score
AI commentary
News tone is favorable following strong Q2 results, raised guidance, LINZESS growth, debt repayment, and STARS-2 recruitment. Social coverage, options data, short interest, employee sentiment, and verified post-print market reaction are unavailable; the positive news tone should not be treated as confirmation of a durable rerating.
RankAlpha Sentiment Codex - 2026-08-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-15eventSTARS-2 Phase 3 recruitment executionHigh impact
The confirmatory Phase 3 STARS-2 trial of apraglutide in short bowel syndrome with intestinal failure is actively recruiting. Enrollment progress and development execution are the clearest forward monitors, but timing for interim milestones was not disclosed. [#SEC-8K-2026-08-06]
2026-11-15catalystLINZESS execution and raised 2026 guidanceHigh impact
Q2 U.S. LINZESS net sales were $282 million and year-to-date sales were $555 million, up 44% year over year. Ironwood raised full-year LINZESS, total revenue, and adjusted EBITDA guidance. Improved net pricing and mid-single-digit prescription-demand growth support the near-term case, although much of the update may be reflected in the stock. [#SEC-8K-2026-08-06]
2027-08-17catalystApraglutide diversification potentialHigh impact
Successful STARS-2 execution and subsequent regulatory progress could create a second commercial growth driver, but clinical, regulatory, and commercialization outcomes remain unproven. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-25 • Updated nightlySource: Internal modelMethodology